Physicians' Academy for Cardiovascular Education

Improved health status with SGLT2-inhibitor in HFrEF

3' education - Nov. 25, 2019 - Prof. Mikhail Kosiborod - Kansas City, MO, USA - AHA 2019, Philadelphia

Educational information

This video was recorded at the AHA in Philadelphia, USA, on november 17, 2019.


Dr. Mikhail Kosiborod is a cardiologist, Vice President of Research at Saint Luke’s Health System, Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardio Metabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, and Professor of Medicine at the University of Missouri-Kansas City.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: